49 Wealth Management’s GT Biopharma GTBP Stock Holding History

49 Wealth Management’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2,560	Closed	-$31.3K	–	267
2026 Q2	$31.3K	Buy	+2,560	New	+$26K	0.01%	189

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Main Street Group Glen Allen, Virginia $445M AUM 22.95% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

49 Wealth Management's GTBP Position: Q3 2026 in Review

49 Wealth Management sold out of GT Biopharma (GTBP) in Q3 2026, closing a stake of 2,560 shares — an estimated $31.3K sold.

49 Wealth Management first reported a position in GTBP in Q2 2026 and held it in 1 quarter. The position peaked at $31.3K in Q2 2026. 20 funds tracked by Wall St. Rank hold GTBP as of Q3 2026.

49 Wealth Management reported no remaining GT Biopharma position as of Q3 2026 after selling out during the quarter.
49 Wealth Management sold 2,560 GT Biopharma shares in Q3 2026, an estimated $31.3K.
49 Wealth Management first reported a position in GT Biopharma in Q2 2026 and held it in 1 quarter.
49 Wealth Management's GT Biopharma position peaked at $31.3K in Q2 2026.
20 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2026.

Based on 49 Wealth Management's 13F filing for Q3 2026, filed 13 Nov 2026.